Press Detail





Biotest AG: Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins


Biotest AG / Key word(s): Alliance

2015-07-01 / 08:30


/
PRESS RELEASE

Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins

- The agreement relates to CEVEC's proprietary cell line (expression system) for the development, production and commercialization of proteins to treat the symptoms of Haemophilia patients


Dreieich, July 1, 2015. Biotest AG and CEVEC Pharmaceuticals GmbH (CEVEC) today announce that the companies have signed a licence agreement.

The agreement relates to CEVEC's proprietary CAP(R) cells used for the production of recombinant proteins. Under the license agreement, Biotest utilizes CEVEC's expression system for the development, production and commercialization of these proteins, for example to treat haemophilia patients.

"The technology from CEVEC with its cell expression system is an ideal complement for the future production of Biotest's recombinant candidates in development" says Dr. Jörg Schüttrumpf, Senior Vice President Global Research Biotest.

About CEVEC's Technology
CEVEC's CAP(R) expression system comprises a comprehensive panel of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities. The system enables the manufacture of difficult to express therapeutic glycoproteins, such as coagulation factors, with tailor-made or fully human glycosylation patterns.

About CEVEC:
Privately held CEVEC Pharmaceuticals GmbH is a global solution provider for the production of biopharmaceuticals based in Cologne, Germany. The Company's technologies, including CAP(R)Go and CAP(R)GT are based on a unique human cell expression system.
The CAP(R)Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The CAP(R)GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors.
Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology forms one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the cGMP production in CAP(R)Go and CAP(R)GT cells.

 

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
email: investor_relations@biotest.de

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

 





2015-07-01 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de



373747  2015-07-01